In our experience, both histological (n = 110, 65.9%) and cytological (n = 57, 34.1%) samples were analyzed, strongly supporting the evidence that evaluation of PD-L1 expression levels and molecular profiling of advanced stage NSCLC patients is feasible by using both types of specimens [21,22,29,30]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.